Skip to main content
. Author manuscript; available in PMC: 2023 Jun 20.
Published in final edited form as: ACS Chem Biol. 2022 Nov 3;17(11):3229–3237. doi: 10.1021/acschembio.2c00706

Figure 5 ∣. eIF3i complexes with CRBN on lenalidomide treatment in MM.1S cells after the degradation of other substrates.

Figure 5 ∣

(a) CRBN interactome before IKZF1 degradation (time = 0 h) or after IKZF1 degradation (time = 48 h, 10 μM lenalidomide) by coimmunoprecipitation of endogenous CRBN with 50 μM lenalidomide. The significantly enriched region of proteins from MM.1S at time = 0 h is shaded in red. The significantly enriched region of proteins from MM.1S at time = 24 h is shaded in blue. (b) Endogenous CRBN coimmunoprecipitation with or without lenalidomide in MM.1S before and after lenalidomide-mediated target degradation. (c) Schematic model of CRBN–lenalidomide–eIF3i interaction in MM.1S after IKZF1 is degraded.